Results 71 to 80 of about 8,266 (211)
The conducting airways before and after gender‐affirming hormone therapy in transgender individuals
Experimental Physiology, EarlyView.Abstract On average, females have smaller airways than males. The largest discrepancy in airway size occurs during puberty, when endogenous sex hormone concentrations diverge between males and females. Transgender individuals often use gender‐affirming hormone therapy (GAHT) to align physical characteristics with gender identity.
Shalaya Kipp +7 more
wiley +1 more source
Minoxidil: New Areas of Opportunity!
Introduction: Minoxidil is a compound chemically synthesized in the laboratory, it underwent clinical trials in hypertensive patients in 1961. Objective: To carry out art history based on an exhaustive search of the national and international medical ...
Oscar Gregorio Ramírez Gamboa +10 more
core +1 more source
Clinical use of Minoxidil (Loniten)
, 1981 The powerful peripheral vasodilator minoxidil, in a dose of 5-40 mg daily, controlled the previously refractory blood pressure in 45 out of 47 patients for periods up to fifty-seven months.
P F B O'Regan, F D Thompson, A M Joekes
core +1 more source
Frontiers in MedicineBackgroundAndrogenetic alopecia is the most prevalent form of progressive hair loss. Minoxidil is widely regarded as a standard treatment for this condition.
Yinfeng Xia +3 more
doaj +1 more source
Design Considerations for Polymer–Deep Eutectic Solvent Hybrid Systems for Transdermal Drug Delivery
Journal of Applied Polymer Science, Volume 143, Issue 40, October 20, 2026.Deep eutectic solvents (DESs) act as tunable, green excipients that modulate polymer structure–property relationships to enhance drug solubility, skin permeation, stability, and controlled release. Through hydrogen‐bond interactions, DES–polymer hybrid systems enable improved transdermal performance, offering a rational, design‐driven platform for ...
Madhavi Kailas Kapale +3 more
wiley +1 more source
Aromatic C-nitrosation of a bioactive molecule. Nitrosation of minoxidil
, 2011 Minoxidil (2,4-diamino-6-(piperidin-1′-yl)pyrimidine N(3)-oxide; CASRN 38304-91-5) is a bioactive molecule with several nitrosatable groups widely used as an antihypertensive and antialopecia agent. Here the nitrosation of minoxidil was investigated. The
Calle, Emilio +7 more
core +1 more source
International Journal of Dermatology, Volume 65, Issue 10, Page 2091-2101, October 2026.A panel of 18 dermatologists participated in a three‐round Delphi‐based consensus process to generate a standardized framework for the diagnosis and management of alopecia areata (AA) in Asia Pacific. Recommendations focus on practicality and clinical relevance within the regional context.
Rodney Sinclair +17 more
wiley +1 more source
Topical minoxidil gender prices
Supplemental table I. Cost of topical minoxidil solutions available at major retailers and telehealth servicesSupplemental table I legend: n, number of products averagedAll prices are standardized to 60 mL volume.
Ong, M (via Mendeley Data)
core +1 more source
MINOXIDIL ORAL E SUA EFICÁCIA NO TRATAMENTO DA ALOPECIA [PDF]
Minoxidil began to be implemented in the 1970s to treat severe refractory hypertension due to its vasodilatory properties. Unintentionally, early trials of oral minoxidil as an antihypertensive medication documented side effects such as hypertrichosis ...
Azara de Oliveira, Eric +4 more
core +1 more source
Direct Effects of Minoxidil on Epidermal Cells in Culture [PDF]
, 1984 Minoxidil, a potent antihypertensive agent, induces generalized hypertrichosis when administered systemically, or localized hair regrowth when applied topically to sites of severe alopecia areata.
Weiss, Virginia C. +4 more
core +1 more source